Literature DB >> 23808868

Preliminary evaluation of a model of stimulant use, oxidative damage and executive dysfunction.

Theresa Winhusen1, Jessica Walker, Gregory Brigham, Daniel Lewis, Eugene Somoza, Jeff Theobald, Veronika Somoza.   

Abstract

BACKGROUND: Illicit stimulant use increases oxidative stress and oxidative stress has been found to be associated with deficits in memory, attention and problem-solving.
OBJECTIVE: To test a model of the association among oxidative DNA damage, a severe form of oxidative stress, and stimulant use, executive function and stimulant-use outcomes.
METHODS: Six sites evaluating 12-step facilitation for stimulant abusers obtained peripheral blood samples from methamphetamine-dependent (n = 45) and cocaine-dependent (n = 120) participants. The blood samples were submitted to a comet assay to assess oxidative DNA damage. Executive Dysfunction was assessed with the Frontal Systems Behavior Scale (FrSBe), which is a reliable and valid self-report assessment of executive dysfunction, disinhibition and apathy. Stimulant-use measures included self-reported stimulant use and stimulant urine drug screens (UDS).
RESULTS: While more recent cocaine use (<30 days abstinence) was associated with greater oxidative DNA damage (W = 2.4, p < 0.05, d = 0.36), the results did not support the hypothesized relationship between oxidative DNA damage, executive dysfunction and stimulant use outcomes for cocaine-dependent patients. Support for the model was found for methamphetamine-dependent patients, with oxidative DNA damage significantly greater in methamphetamine-dependent patients with executive dysfunction (W = 2.2, p < 0.05, d = 0.64) and with executive dysfunction being a significant mediator of oxidative DNA damage and stimulant use during active treatment (ab = 0.089, p < 0.05). As predicted, neither disinhibition nor apathy were significant mediators of oxidative damage and future stimulant use.
CONCLUSION: These findings provide preliminary support for a model in which oxidative damage resulting from methamphetamine use results in executive dysfunction, which in turn increases vulnerability to future stimulant use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23808868      PMCID: PMC4042831          DOI: 10.3109/00952990.2013.798663

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  37 in total

Review 1.  Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence.

Authors:  Marie-Laure Ancelin; Yves Christen; Karen Ritchie
Journal:  Dement Geriatr Cogn Disord       Date:  2007-05-10       Impact factor: 2.959

Review 2.  Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

3.  Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys.

Authors:  Jie Yuan; George Hatzidimitriou; Pranav Suthar; Melanie Mueller; Una McCann; George Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2005-11-17       Impact factor: 4.030

Review 4.  Methamphetamine influences on brain and behavior: unsafe at any speed?

Authors:  John F Marshall; Steven J O'Dell
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

5.  Neurocognitive deficits in cocaine users: a quantitative review of the evidence.

Authors:  Diana Jovanovski; Suzanne Erb; Konstantine K Zakzanis
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

6.  Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells.

Authors:  H Fai Poon; Laila Abdullah; Myles A Mullan; Michael J Mullan; Fiona C Crawford
Journal:  Neurochem Int       Date:  2006-09-07       Impact factor: 3.921

7.  Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function.

Authors:  Dawn I Velligan; Janice L Ritch; Dawen Sui; Margaret DiCocco; Cindy D Huntzinger
Journal:  Psychiatry Res       Date:  2002-12-30       Impact factor: 3.222

Review 8.  Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs.

Authors:  Teresa Cunha-Oliveira; Ana Cristina Rego; Catarina R Oliveira
Journal:  Brain Res Rev       Date:  2008-03-27

9.  Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease.

Authors:  Deborah A Cahn-Weiner; Janet Grace; Brian R Ott; Hubert H Fernandez; Joseph H Friedman
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  2002-06

10.  Abnormal brain structure implicated in stimulant drug addiction.

Authors:  Karen D Ersche; P Simon Jones; Guy B Williams; Abigail J Turton; Trevor W Robbins; Edward T Bullmore
Journal:  Science       Date:  2012-02-03       Impact factor: 47.728

View more
  4 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary study.

Authors:  Jessica Walker; Theresa Winhusen; Jayne M Storkson; Daniel Lewis; Michael W Pariza; Eugene Somoza; Veronika Somoza
Journal:  Hum Psychopharmacol       Date:  2014-11       Impact factor: 1.672

3.  Long-term functioning to provide empirical support for the clinical relevance of treatment outcomes for methamphetamine use disorders.

Authors:  André Q C Miguel; Crystal L Smith; Ekaterina Burduli; John M Roll; Sterling McPherson
Journal:  J Subst Abuse Treat       Date:  2021-01-14

Review 4.  The Role of Oxidative Stress in Methamphetamine-induced Toxicity and Sources of Variation in the Design of Animal Studies.

Authors:  Kate McDonnell-Dowling; John P Kelly
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.